A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 4-HC / 4-hydroperoxycyclophosphamide

[Related PubMed/MEDLINE]
Total Number of Papers: 212
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   4-HC  (>> Co-occurring Abbreviation)
Long Form:   4-hydroperoxycyclophosphamide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide. c-PARP, CPA, p-AKT
2019 Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. 5-FU, UFT
2019 The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway. 2-F-araA, LN, MCL, MKI67, PB, STAT5B
2018 Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. AML, BU, DAC, FLT3-ITD
2018 Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway. FLSs, MTX, P-gp, RA, RT-PCR
2017 Short-term exposure of human ovarian follicles to cyclophosphamide metabolites seems to promote follicular activation in vitro. AMH, PM
2016 Protective effect of Korean Red Ginseng against chemotherapeutic drug-induced premature catagen development assessed with human hair follicle organ culture model. CIA, KRG
2015 Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney. AQP2, IMCD, NKCC2, NSIAD, V2R
2014 Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. EFS, LCLs, PM, SNPs
10  2012 Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. CY
11  2011 Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. ABMT, CI, EFS, OS
12  2011 The role of proximal nephron in cyclophosphamide-induced water retention: preliminary data. AQP1, AQP7, PTCs
13  2008 Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. CY, MCL, SCID
14  2008 The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. 5-FU
15  2007 Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. BSO, FSH, TUNEL
16  2007 Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. HFs
17  2007 Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. mAb, ROS, ssDNA, TUNEL, TUNEL
18  2007 Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. ALDH, ALDH1A1, PI
19  2007 RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. ALDH1A1, ATRA, CP
20  2007 The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. ---
21  2007 The role of autologous transplantation for acute myeloid leukemia in first and second remission. AML, APL, ASCT, ATRA, EFS
22  2006 Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells. MMP-2
23  2006 Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. CPA
24  2006 Ex vivo expansion of mafosfamide-purged PBPC products. MF, rh, SRC, TPO
25  2005 Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. ---
26  2005 Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. ALDH, ATRA
27  2004 Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells. ATP
28  2004 Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. 4-HDC, ADR, CY, FasL, MTX, OS
29  2004 Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. 8-oxodG, CP
30  2003 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. PBPCs
31  2003 Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. ADR
32  2002 Aldehyde-dehydrogenase gene-transduced hematopoietic cell line K562 overcomes the cytoxicity of cyclophosphamide in vitro. ---
33  2002 Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC). ATP, SPRM
34  2002 UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. ---
35  2002 [Electroporation-mediated gene transduction and expression of class 1 aldehyde dehydrogenase (ALDH1) and multidrug resistance gene (MDR1)]. RT, VCR
36  2001 A bicistronic retroviral vector to introduce drug resistance genes into human umbilical cord blood CD34+ cells to improve combination chemotherapy tolerance. ALDH1, FACS, MTT, PCR, RT
37  2001 Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. EDR
38  2001 DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. CLL
39  2001 Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. MTX
40  2001 Genetic modification of hematopoietic progenitor cells for combined resistance to 4-hydroperoxycyclophosphamide, vincristine, and daunorubicin. ALDH-3, MACS, MDR1, PBPC
41  2001 L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model. BSO
42  2001 The cellular and molecular basis of health benefits of grape seed proanthocyanidin extract. GSPE, IDA
43  2001 The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. AML
44  2001 [A retroviral bicistronic strategy for efficient coexpression of ALDH1 and mdr1]. FCM, G1Na-AIM, IRES, mdrl, PCR, VCR
45  2001 [Improvement of combination chemotherapy tolerance of human umbilical cord blood CD(34)(+) cells transducted with double drug resistance genes by a bicistronic retroviral vector]. ALDH3, MACS
46  2000 Camptothecin analogues with enhanced antitumor activity at acidic pH. CMMDC, CPT, MDC, TPT
47  2000 Chemopreventive effects of grape seed proanthocyanidin extract on Chang liver cells. GSPE, IDA, RT-PCR
48  2000 Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. BCNU, BG, CHO, CHOWTAGT, PM
49  2000 Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. ---
50  2000 Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. ALDH1, AS
51  2000 Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. ASCT, MAF
52  2000 [Study on expression and resistance of the double drug resistance genes transduced into human umbilical cord blood CD34+ cells mediated by bicistronic retroviral vector]. ALDH1
53  1999 Amelioration of the cytotoxic effects of chemotherapeutic agents by grape seed proanthocyanidin extract. GSPE, IDA
54  1999 Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging. 5-FU
55  1999 Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. 4-HCR, O6-BG
56  1999 Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine. B-CLL, CdA, CP, MAF
57  1999 Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. ---
58  1999 Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. 4-HDC, PM
59  1998 Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. ABMT, AML, DFS
60  1998 Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. ALDH1, G6PD
61  1998 Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. topo IIalpha
62  1998 Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood. CFUs, G-PBSC, GFmix, IL, LTC-ICs
63  1998 In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. ALDH1
64  1998 Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. ---
65  1998 Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. CPT, topo I, TPT
66  1998 Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). FCA
67  1997 Fibronectin fragment-facilitated retroviral transfer of the glutathione-S-transferase pi gene into CD34+ cells to protect them against alkylating agents. AA, ADM, GST-pi
68  1997 Increased growth inhibition of human chronic myelogenous leukemic cells by a combination of c-myb antisense oligonucleotide and 4-hydroxyperoxycyclophosphamide in vitro. CML
69  1997 Protection of hematopoietic progenitors from ultraviolet C by interleukin-1 and tumor necrosis factor-alpha. CFCs, IL-1, TNF-alpha, UVC
70  1997 [Hematopoietic stem cell transplantation for children with cancer]. BMT
71  1996 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement. BM, CR, NHL, OS, PR
72  1996 Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. BCNU, CI, TPT
73  1996 Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. ABMT, AML, CFU-GM
74  1996 Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. alpha-IFN, CML, gamma-IFN
75  1996 Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. ---
76  1996 Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. CP, PM
77  1996 Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. ALDH1, PCR
78  1996 Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. ICLs
79  1996 Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. ---
80  1996 Use of amifostine in bone marrow purging. ---
81  1995 Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. ABMT, MNC
82  1995 Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. CP, NB
83  1995 Effect of stem cell factor on myelopoiesis potential in human Dexter-type culture systems. mAb, SCF
84  1995 Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. ---
85  1995 Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex. ALAK, BM, BMT, NK, rIL-2, Roq
86  1995 Generation of human natural killer cells from pharmacologically purged bone marrow. ABMT, BM, NK
87  1995 Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. AML, BU, CR, CY, TBI, TNC
88  1995 Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. ALDH1, DEAB, IL-1, TNF-alpha
89  1995 Interleukin-11 (IL-11) and IL-9 counteract the inhibitory activity of transforming growth factor beta 3 (TGF-beta 3) on human primitive hematopoietic progenitor cells. BM, GM-CSF, IL-11, TGF-beta 3
90  1995 Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. ---
91  1995 Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. ADH, ISCs, PM
92  1995 Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. ---
93  1995 Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. CFU-GM, PBPC
94  1995 The effects of interleukin-1 beta and tumor necrosis factor-alpha on in vitro colony formation by human hematopoietic progenitor cells exposed to doxorubicin or hydroquinone. BM, BMMNC, DX, HPC, HQ, IL-1 beta, pHPC, TNF-alpha
95  1994 31P NMR spectroscopic studies of the effects of cyclophosphamide on perfused RIF-1 tumor cells. ---
96  1994 A combination of anti-CD15 monoclonal antibody PM-81 and 4-hydroperoxycyclophosphamide augments tumor cytotoxicity while sparing normal progenitor cells. ABMT, AML, BM, mAb
97  1994 Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. ABMS
98  1994 Antileukemic activity of phenylalanine methyl ester (PME): a lysosomotropic peptide methyl ester. ALL, AML, PLL, PME
99  1994 Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. BM
100  1994 CAI: effects on cytotoxic therapies in vitro and in vivo. CDDP